Content - Industry

Industry

Most SAKK studies are treatment optimization studies for the further development of existing treatments. These SAKK studies are financed to a certain extent from industry funds. Precisely in the case of cancer medicines synergies can arise between academic research groups and industry, because even only slightly modified treatments can lead to a further improvement in results or a reduction of side effects. In this field, the SAKK plays a key role, because its many years of experience and its existing network enable it to carry out interdisciplinary multicentre studies. The network includes in particular also centres that can conduct Phase I studies.

The SAKK has formulated a set of guidelines for its cooperation with pharmaceutical companies.

The people who work for the SAKK are also guided in their activities by the basic principles of the guidelines issued by the Swiss Academy of Medical Sciences (SAMS) on collaboration between the medical profession and industry.

 

SAKK Industry Pool – sponsoring options

The SAKK maintains an SAKK Industry Pool to cultivate relations with pharmaceutical companies. The purpose of the SAKK Industry Pool is to establish a platform for regular exchange between the SAKK and pharmaceutical companies. At present, about 30 pharmaceutical companies belong to the SAKK Industry Pool. The members of the Industry Pool thus have the opportunity to increase their visibility in the SAKK network and to exchange information regularly with SAKK representatives.

 

Membership of the SAKK Industry Pool offers the following advantages:

  • Participation in the SAKK industry pool meetings
  • Participation in the half-year general meetings of the SAKK twice yearly (in June and November) and the public part of the project group meetings
  • Various SAKK publications, e.g. SAKK newsletter, Swiss Cancer Bulletin and annual report
  • The opportunity to organize a satellite symposium at the half-year meeting in June and November
  • The opportunity to rent a “discussion corner” at the half-year meeting in June and November
  • The opportunity to advertise in the Swiss Cancer Bulletin

 

SAKK Industry Pool consists of the following members:

  • AbbVie AG
  • Amgen Switzerland AG
  • Astellas Pharma AG
  • AstraZeneca AG
  • Bayer (Schweiz) AG
  • Boehringer Ingelheim (Schweiz) GmbH
  • Bristol-Myers Squibb SA
  • Celgene GmbH
  • Eli Lilly (Suisse) SA
  • Genomic Health Intl' Sàrl
  • Gilead Sciences Switzerland Sàrl
  • Incyte Inc.
  • Janssen-Cilag AG
  • Jazz Pharmaceuticals
  • Lipomed AG
  • Merck (Schweiz) AG
  • MSD Merck Sharp & Dohme AG
  • Mundipharma Medical Company
  • Novartis Pharma (Schweiz) AG
  • Pfizer AG
  • PharmaMar S.A.
  • Pierre Fabre Pharma AG
  • Roche Pharma (Schweiz) AG
  • Sandoz Pharmaceuticals AG
  • Sanofi-Aventis (Schweiz) AG
  • Shire
  • Takeda Pharma AG
  • TESARO Bio GmbH
  • Teva Pharma AG
  • Vifor AG

 

If you have any questions or are interested in becoming a member of the SAKK Industry Pool, please contact Dennis Ammann, dennis.ammann@anti-cluttersakk.ch.